Back

Sunshine Biopharma advances coronavirus drug into IND-enabling studies

Verifying
  • Sunshine Biopharma advanced its lead coronavirus drug candidate into IND-enabling studies.
  • $1.02 was the company’s premarket share price after a 0.97% decline.
  • The candidate suppressed pulmonary viral replication in infected K18-hACE2 mice.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.